Real-world Use of Cefiderocol in Neonatal and Pediatric Populations: A Multicenter Case Series and Systematic Review

The Pediatric Infectious Disease Journal 2026

View at publisher
Authors: Chrysanthi Mantsiou, Argyro Ftergioti, Elif Böncüoğlu, Elif Kıymet, Angeliki-Eleni Sfetsiori, Angeliki Syggelou, Filippos Filippatos, Dimitrios Doganis, Maria Tsolia, Athanasios Michos, Emmanuel Roilides, Elias Iosifidis
DOI: 10.1097/inf.0000000000005134
Cited by: 4
References: 35

Abstract

BACKGROUND: Cefiderocol is a novel siderophore-conjugated cephalosporin with activity against antimicrobial-resistant Gram-negative bacteria. Despite increasing off-label use in critically ill neonates and children, data on its safety and effectiveness remain limited. METHODS: We performed a retrospective case series of neonatal and pediatric patients (≤18 years) who received off-label cefiderocol across 3 tertiary-care hospitals in Greece for suspected or documented infections due to multidrug-resistant Gram-negative bacteria. We also conducted a systematic review of pediatric cases published through June 2025. RESULTS: Fifteen patients [median age 65 months (range 4-183)] received 21 cefiderocol courses. The systematic review identified 37 additional treatment courses (32 patients, 6 of them

Fields of Study & Subjects

Neonatal and Maternal Infections Antimicrobial Resistance in Staphylococcus Antibiotics Pharmacokinetics and Efficacy

Publication details

Journal / source
The Pediatric Infectious Disease Journal
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
45
Issue
7
Pages
603–609
Publication date
5 January 2026
Language
EN